Palo Alto, CA, September 20, 2012 - G-Tech Obtains IRB Approval for Initial IBS Clinical Study

G-Tech Inc. received approval to launch a 6-month, 60-subject clinical research study designed to record abnormal myoelectrical activity in subjects with functional GI disorders.  The study will monitor and evaluate abdominal pain associated with constipation and/or diarrhea, often diagnosed as irritable bowel syndrome, or IBS.

G-Tech’s unique diagnostic approach measures myoelectric signals from GI organs, analogous to an ECG (electrocardiogram) for the gut.  Published literature has established that the patterns of electric signals associated with organ activity differ between healthy subjects and those with GI disorders.  

“The objective of this study is to measure the electrical signals at the skin surface and differentiate patterns of myoelectric activity in healthy subjects from the electrical patterns in symptomatic subjects,” said G-Tech CEO Steve Axelrod, Ph.D. “By quantifying these differences, G-Tech will supply a powerful diagnostic tool useful to the millions of Americans afflicted with abdominal pain, constipation, diarrhea and bloating.”  Accurate diagnosis may lead to more effective and targeted therapy resulting in a significant cost reduction due to reduced chronic office visits that can occur with patients with functional GI disorders such as IBS.

Enrollment in the trial will begin immediately in the San Francisco Bay Area.

#   #   #

G-Tech Inc. is an early-stage medical device company dedicated to developing low-cost, non-invasive, diagnostic solutions for patients with chronic gastrointestinal disorders. The company headquarters are located at 1121 San Antonio Rd Suite D203, Palo Alto, CA 94303.  For further information, please go to or send an email to